FPR2 and prostate adenocarcinoma: Indeed, in the same study, Jia et al. demonstrated that tumor size was reduced in NOD/SCID mice injected with human prostate adenocarcinoma LNCaP cells when the mice were treated four weeks with PBP10 (10 μg/mL), an ALX/FPR2 inhibitor, compared to the untreated LNCaP cell-injected NOD/SCID mice [229].